A Study of Pertuzumab in Participants With Prostate Cancer

NCT02480010 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

68

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated at the time of interim analysis since none of the participants showed a PSA response.

Conditions

Prostate Cancer

Interventions

DRUG: Pertuzumab

Sponsor

Hoffmann-La Roche